ASCI

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Retrieved on: 
Wednesday, January 10, 2024
Stanford University, Leukemia, Monroe Dunaway Anderson, Research, Metastasis, Ipilimumab, Cancer, Autoimmune disease, CODEX, GBM, University, National academy, Bladder cancer, MD Anderson Cancer Center, RNA, Teal, CD28, Defense, EZH2, Nobel Prize, Invention, Translational research, Health, Cell biology, Pathology, Woman, Immunotherapy, SAB, Emil Frei, Patient, Associate, MD, Roche, Burroughs Wellcome Fund, Society, FDA, ATAC, ASCI, Doctor of Philosophy, Clinical trial, Immune system, Pharmaceutical industry

Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.

Key Points: 
  • Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.
  • He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine.
  • Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
  • This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer.

Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Retrieved on: 
Thursday, April 13, 2023
Biotechnology, Genetics, Health, Oncology, Damon Runyon Cancer Research Foundation, ASCI, KRAS, American Society for Clinical Investigation, Partnership, Senior, Research, Cancer, NIH, Axicabtagene ciloleucel, National Institutes of Health, Associate, Bangladesh Technical Education Board, National Cancer Institute, Science, National Institutes of Health MERIT Award, Cell engineering, MD, Patient, Engineering, Cell, MSK, Fred Hutchinson Cancer Research Center, Therapy, NCI, Society, Pharmaceutical industry, Klebanoff–Saric Wind Tunnel

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.
  • “We are committed to pushing forward a first-in-class pipeline of treatments targeting oncogene driver mutations for patients with solid tumor malignancies,” said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics.
  • Dr. Klebanoff has contributed to the successful early phase development of numerous T cell-based therapies, notably Yescarta® (axicabtagene ciloleucel) at NCI.
  • “As a practicing medical oncologist, my singular professional focus and that of my lab is to address the urgent needs of patients with cancer.

THE PROSTATE CANCER FOUNDATION APPOINTS WILLIAM K. OH, MD, AS CHIEF MEDICAL OFFICER

Retrieved on: 
Wednesday, November 16, 2022
Oncology, Quality of life, ASCI, Hospital, MD, Prostate cancer, American Cancer Society, New York University Grossman School of Medicine, Precision medicine, Prostate Cancer Foundation, American Urological Association, Man, ASCO, Society, Data, GU, Harvard Medical School, Icahn School of Medicine at Mount Sinai, Research, NCI, Hematology, Internal medicine, Safety, Death, ACS, Patient, Book, Brigham and Women's Hospital, PCF, Division, CEO, AUA, Clinical Cancer Research, University School, American Society for Clinical Investigation, Dana–Farber Cancer Institute, Steven Naifeh, Yale College, Science, CMO, Disease, Prostate, American Society of Clinical Oncology, Medical imaging, New York (magazine)

LOS ANGELES, Nov. 16, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF), the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research, today announced that William K. Oh, MD, an internationally recognized genitourinary (GU) oncologist with expertise in the use of systemic treatments for prostate cancer, has been appointed Chief Medical Officer (CMO), a newly-created leadership position.

Key Points: 
  • LOS ANGELES, Nov. 16, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF), the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research, today announced that William K. Oh, MD, an internationally recognized genitourinary (GU) oncologist with expertise in the use of systemic treatments for prostate cancer, has been appointed Chief Medical Officer (CMO), a newly-created leadership position.
  • "In his role as Chief Medical Officer, Dr. Oh will be a key leader of the PCF as it works towards its mission of reducing death and suffering from prostate cancer worldwide."
  • The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research.
  • PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease.

GO2 for Lung Cancer Honors Champions of the Lung Cancer Community at Simply the Best XVII Gala

Retrieved on: 
Monday, November 14, 2022
SAN, Doctor of Philosophy, Vanderbilt University Medical Center, Family, Lung cancer, ASCI, Squamous cell carcinoma, Health, Technology, MD, American Association, Work, Vanderbilt-Ingram Cancer Center, Friends, American Society for Clinical Investigation, American Association for Cancer Research, Physician, Survivor, Leadership, Bonnie J. Addario Lung Cancer Foundation, Best, Medicine, Caregiver, Hope, ASCO, Society, Editorial board, Research, Daiichi Sankyo, ADC, Multimedia, Patient, AACR, International Association, Division, CEO, Associate, Large-cell lung carcinoma, JCO, Disease, American Society of Clinical Oncology, Uranium, Pharmaceutical industry, Medical imaging

SAN CARLOS, Calif.andWASHINGTON, Nov. 14, 2022 /PRNewswire/ -- GO2 for Lung Cancer (GO2) honored leadership in lung cancer research and treatment, as well as dedicated caregiving, at its Simply the Best XVII Gala held in San Francisco on November 12.

Key Points: 
  • SAN CARLOS, Calif.andWASHINGTON, Nov. 14, 2022 /PRNewswire/ -- GO2 for Lung Cancer (GO2) honored leadership in lung cancer research and treatment, as well as dedicated caregiving, at its Simply the Best XVII Gala held in San Francisco on November 12.
  • Daiichi Sankyo was honored with this award for their commitment to advancing lung cancer oncology discovery to meet the needs of all patients.
  • "I'm so honored to be recognized by GO2 for Lung Cancer for my work to bring targeted, personalized and more effective treatments to lung cancer patients," said Dr. Lovly.
  • GO2 for Lung Cancer is leading the charge to confront lung cancer and we're taking it on relentlessly from every front, every day.

Nominations Open for 10th Annual International Harrington Prize for Innovation in Medicine

Retrieved on: 
Monday, July 25, 2022
Lecture, University Hospitals Cleveland Medical Center, NHLBI, Association, Antibody, Diabetes, Rockefeller University, NIH, Society, University, NIAMS, Disorder, Sickle cell disease, Doctor of Philosophy, American Physician Scientists Association, CAR, Human papillomavirus infection, Massachusetts General Hospital, Leptin, Lists of diseases, Vanderbilt University, Marfan syndrome, Mount Sinai Hospital, National Cancer Institute, LDL, COVID-19, Cervical cancer, All India Mahila Congress, Thalassemia, Organization, Journal, University of Texas Southwestern Medical Center, Creativity, Science, List, Patient, University of Copenhagen, University of Pennsylvania, Biology, American Society for Clinical Investigation, PCSK9, ASCI, APSA, Johns Hopkins University, AAP, Harvard University, Pharmaceutical industry, Vaccine, Medicine, MD

CLEVELAND, July 25, 2022 /PRNewswire/ -- National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. 

Key Points: 
  • CLEVELAND, July 25, 2022 /PRNewswire/ --National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.
  • The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), one of the nation's oldest and most respected medical honor societies.
  • Harrington Discovery Institute is a nonprofit institute dedicated to helping physician-scientists accelerate promising discoveries into medicines for unmet needs.
  • A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee.

International Harrington Prize Jointly Awarded to Drs. James Crowe and Michel Nussenzweig

Retrieved on: 
Thursday, March 24, 2022
University of Texas Southwestern Medical Center, AAP, National Cancer Institute, Mount Sinai Hospital, Cardiology, Rockefeller University, University, Johns Hopkins University, Biochemistry, LDL, Massachusetts General Hospital, Pediatrics, PCSK9, All India Mahila Congress, Harvard University, University Hospitals Cleveland Medical Center, Disorder, Biology, NIH, ASCI, Science, Degenerative disease, Thalassemia, Doctor of Philosophy, Disease, Severe acute respiratory syndrome coronavirus 2, Marfan syndrome, Diabetes, Society, COVID, Patient, Creativity, Antibody, Human, Academic health science centre, Microbiology, University of Pennsylvania, Pathology, CAR, Immunology, Human papillomavirus infection, COVID-19, Sickle cell disease, Northwestern Medicine, HHMI, Division, Pharmaceutical industry, Vaccine, MD, Medicine

CLEVELAND, March 24, 2022 /PRNewswire/ -- The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and Professor, Departments of Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, and Michel C. Nussenzweig, MD, PhD, Investigator, HHMI, and Zanvil A. Cohn and Ralph M. Steinman Professor, The Rockefeller University. The award recognizes their groundbreaking work, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.

Key Points: 
  • Dr. Crowe has advanced the discovery of human monoclonal antibodies for many of the most pathogenic viruses that cause human disease.
  • Dr. Nussenzweig showed that antibodies cloned directly from humans can be a safe and effective treatment against viral infections when passively transferred to other humans.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from eight countries before selecting the 2022 Harrington Prize recipients.
  • Crowe and Nussenzweig are extraordinary physician-scientists who took distinct and separate paths but arrived at the same endpoint.

DGAP-News: NEW XFINITY REWARDS PROGRAM UNLOCKS A WORLD OF UNFORGETTABLE EXPERIENCES, EARLY ACCESS TO THE LATEST TECHNOLOGIES, AND SPECIAL PERKS AND DISCOUNTS FOR XFINITY CUSTOMERS

Retrieved on: 
Tuesday, March 8, 2022
Diamond, Cleo, Park, American Music Awards, NBCUniversal Television and Streaming, The Mighty Ducks, Universal Pictures, Universal, NASCAR, Universal Parks & Resorts, Human, Program, Sky Studios, NBC, Latin American Music Awards, NBC Sports, Late Night, Wi-Fi, Telemundo, Sport, Nasdaq, ASCI, Universal Orlando, Greeting, Sky News, Love, U.S. Silver & Gold, News, Olympic, Comcast, Aggregation, Cleo TV, Island, VIP, MLB, EST, NBCUniversal, Music, Universal Studios Florida, NHL, AND, Platinum, Technology, NBA, NFL, Comcast Business, Aspire (TV network), Drama, Senior, Bravo, The Heights, XFINITY, Sky Sports, NBC Sports Edge, Amusement arcade, Cryptocurrency, Mail order, Amusement park, Entertainment, Xfinity, Gold, Silver

NEW XFINITY REWARDS PROGRAM UNLOCKS A WORLD OF UNFORGETTABLE EXPERIENCES, EARLY ACCESS TO THE LATEST TECHNOLOGIES, AND SPECIAL PERKS AND DISCOUNTS FOR XFINITY CUSTOMERS

Key Points: 
  • NEW XFINITY REWARDS PROGRAM UNLOCKS A WORLD OF UNFORGETTABLE EXPERIENCES, EARLY ACCESS TO THE LATEST TECHNOLOGIES, AND SPECIAL PERKS AND DISCOUNTS FOR XFINITY CUSTOMERS
    The issuer is solely responsible for the content of this announcement.
  • Comcast today announced the launch of Xfinity Rewards, a rewards program for all customers across the country.
  • 'The entire Xfinity Rewards experience has been shaped and inspired by our customers.
  • Xfinity Rewards is all about unlocking unforgettable experiences - and what better place to start than right at home.

New Xfinity Rewards Program Unlocks a World of Unforgettable Experiences, Early Access to the Latest Technologies, and Special Perks and Discounts for Xfinity Customers

Retrieved on: 
Thursday, March 3, 2022
Other Consumer, Women, Seniors, Men, Other Technology, LGBTQ+, Telecommunications, Software, Family, Networks, Internet, Hardware, Consumer, Electronic Design Automation, Data Management, VoIP, Consumer Electronics, Mobile, Wireless, Technology, Semiconductor, Security, Satellite, Photography, Nanotechnology, Audio, Video, General Entertainment, Teens, Parenting, Entertainment, Children, Baby, Maternity, Diamond, Cleo, Park, American Music Awards, NBCUniversal Television and Streaming, The Mighty Ducks, Universal Pictures, Universal, NASCAR, Universal Parks & Resorts, Human, Wonderful Life, Program, Sky Studios, NBC, Latin American Music Awards, NBC Sports, Late Night, Wi-Fi, Telemundo, Sport, ASCI, Universal Orlando, Greeting, Sky News, Love, U.S. Silver & Gold, News, Olympic, Multimedia, Aggregation, VIP, MLB, EST, NBCUniversal, Music, Universal Studios Florida, NHL, Platinum, Technology, NBA, NFL, Comcast Business, Aspire (TV network), Drama, Senior, Bravo, The Heights, Sky Sports, NBC Sports Edge, Amusement arcade, Cryptocurrency, Mail order, Amusement park, Entertainment, Xfinity, Comcast, Gold, Silver

Comcast today announced the launch of Xfinity Rewards, a rewards program for all customers across the country.

Key Points: 
  • Comcast today announced the launch of Xfinity Rewards, a rewards program for all customers across the country.
  • Xfinity Rewards was built around a simple idea: to give back to customers, just for being a customer, through unique and unforgettable experiences that only Comcast NBCUniversal can deliver.
  • The entire Xfinity Rewards experience has been shaped and inspired by our customers.
  • Xfinity Rewards is all about unlocking unforgettable experiences and what better place to start than right at home.